Amid the firestorm of controversy surrounding drug maker Mylan’s decision to hike up prices for the life-saving EpiPen, actress Sarah Jessica Parker has ended her relationship with the company.
Explaining that she couldn’t condone the pharmaceutical giant’s actions, Parker said on Thursday she would no longer be a company spokesperson.
Her Instagram announcement comes just days after the price of EpiPens rose to more than $600 each.
Parker, who had been involved with an unbranded Mylan ad campaign about anaphylaxis, has a son with a severe peanut allergy.
“I’m left disappointed, saddened and deeply concerned by Mylan’s actions,” Parker wrote, adding, “I hope they…will take swift action to lower the cost to be more affordable for whom it is a life-saving necessity.”
It came on the same day Mylan announced it would expand its patient-assistance program, in order to reduce costs for those who couldn’t afford EpiPens – a move that came one day after the company’s stocks plummeted, Time reports.
Drugs.com describes EpiPen as “an injection containing epinephrine, a chemical that narrows blood vessels and opens airways in the lungs. These effects can reverse severe low blood pressure, wheezing, severe skin itching, hives, and other symptoms of an allergic reaction.”
